Hernández-Díaz S, Rodríguez L A
Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA.
Arch Intern Med. 2000 Jul 24;160(14):2093-9. doi: 10.1001/archinte.160.14.2093.
In the last decades, studies have estimated the upper gastrointestinal tract bleeding/perforation (UGIB) risk associated with individual nonsteroidal anti-inflammatory drugs (NSAIDs). Later analyses have also included the effect of patterns of NSAID use, risk factors for UGIB, and modifiers of NSAID effect.
Systematic review of case-control and cohort studies on serious gastrointestinal tract complications and nonaspirin NSAIDs published between 1990 and 1999 using MEDLINE. Eighteen original studies were selected according to predefined criteria. Two researchers extracted the data independently. Pooled relative risk estimates were calculated according to subject and exposure characteristics. Heterogeneity of effects was tested and reasons for heterogeneity were considered.
Advanced age, history of peptic ulcer disease, and being male were risk factors for UGIB. Nonsteroidal anti-inflammatory drug users with advanced age or a history of peptic ulcer had the highest absolute risks. The pooled relative risk of UGIB after exposure to NSAIDs was 3.8 (95% confidence interval, 3.6-4.1). The increased risk was maintained during treatment and returned to baseline once treatment was stopped. A clear dose response was observed. There was some variation in risk between individual NSAIDs, though these differences were markedly attenuated when comparable daily doses were considered.
The elderly and patients with a history of peptic ulcer could benefit the most from a reduction in NSAID gastrotoxicity. Whenever possible, physicians may wish to recommend lower doses to reduce the UGIB risk associated with all individual NSAIDs, especially in the subgroup of patients with the greatest background risk.
在过去几十年中,已有研究对与个别非甾体抗炎药(NSAIDs)相关的上消化道出血/穿孔(UGIB)风险进行了评估。后续分析还纳入了NSAIDs使用模式的影响、UGIB的危险因素以及NSAIDs效应的调节因素。
通过MEDLINE对1990年至1999年间发表的关于严重胃肠道并发症与非阿司匹林NSAIDs的病例对照研究和队列研究进行系统评价。根据预先设定的标准选择了18项原始研究。两名研究人员独立提取数据。根据研究对象和暴露特征计算合并相对风险估计值。对效应的异质性进行了检验,并探讨了异质性的原因。
高龄、消化性溃疡病史和男性是UGIB的危险因素。年龄较大或有消化性溃疡病史的非甾体抗炎药使用者的绝对风险最高。暴露于NSAIDs后UGIB的合并相对风险为3.8(95%置信区间,3.6 - 4.1)。治疗期间风险持续增加,一旦停药则恢复至基线水平。观察到明确的剂量反应关系。个别NSAIDs之间的风险存在一定差异,但在考虑可比日剂量时,这些差异明显减小。
老年人和有消化性溃疡病史的患者可能从降低NSAIDs的胃毒性中获益最大。只要有可能,医生不妨推荐较低剂量以降低与所有个别NSAIDs相关的UGIB风险,尤其是在背景风险最高的患者亚组中。